Your browser is no longer supported. Please, upgrade your browser. Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
JAZZ [NASD]
Jazz Pharmaceuticals Public Limited Company
Index- P/E405.00 EPS (ttm)0.42 Insider Own3.60% Shs Outstand60.49M Perf Week-2.56%
Market Cap10.29B Forward P/E16.75 EPS next Y10.16 Insider Trans-9.33% Shs Float58.52M Perf Month4.81%
Income32.10M PEG16.46 EPS next Q2.30 Inst Own89.00% Short Float3.98% Perf Quarter5.72%
Sales1.08B P/S9.52 EPS this Y-19.10% Inst Trans1.38% Short Ratio2.90 Perf Half Y19.51%
Book/sh22.23 P/B7.65 EPS next Y22.54% ROA1.10% Target Price194.24 Perf Year48.56%
Cash/sh9.51 P/C17.89 EPS next 5Y24.60% ROE2.50% 52W Range108.58 - 180.00 Perf YTD34.40%
Dividend- P/FCF31.98 EPS past 5Y20.00% ROI13.30% 52W High-5.50% Beta0.65
Dividend %- Quick Ratio3.80 Sales past 5Y66.80% Gross Margin89.40% 52W Low56.66% ATR5.22
Employees870 Current Ratio3.90 Sales Q/Q32.00% Oper. Margin20.50% RSI (14)53.31 Volatility2.95% 2.93%
OptionableYes Debt/Eq1.00 EPS Q/Q-66.70% Profit Margin3.00% Rel Volume0.69 Prev Close169.84
ShortableYes LT Debt/Eq0.99 EarningsNov 04 AMC Payout0.00% Avg Volume805.03K Price170.10
Recom1.80 SMA20-0.10% SMA504.58% SMA20012.79% Volume557,804 Change0.15%
Nov-05-14Upgrade R. F. Lafferty Neutral → Buy $200
May-09-14Reiterated R. F. Lafferty Neutral $140 → $130
Apr-17-14Initiated Canaccord Genuity Buy $163
Mar-07-14Resumed Barclays Overweight $200
Feb-26-14Reiterated Stifel Buy $145 → $195
Jan-14-14Reiterated UBS Buy $130 → $164
Jan-14-14Downgrade R. F. Lafferty Buy → Neutral $140
Dec-06-13Reiterated UBS Buy $110 → $130
Nov-25-13Reiterated FBR Capital Outperform $105 → $198
Nov-25-13Reiterated Barclays Overweight $112 → $130
Nov-13-13Reiterated R. F. Lafferty Buy $102 → $118
Oct-30-13Initiated FBR Capital Outperform $105
Sep-13-13Reiterated UBS Buy $87 → $98
Aug-22-13Initiated R. F. Lafferty Buy $102
Aug-07-13Reiterated UBS Buy $80 → $87
Aug-07-13Reiterated Cantor Fitzgerald Buy $86 → $97
Aug-07-13Reiterated Barclays Overweight $70 → $85
May-31-13Initiated Stifel Buy $80
Mar-11-13Initiated Cantor Fitzgerald Buy $86
Feb-27-13Reiterated UBS Buy $64 → $67
Nov-20-14 03:10PM  Riding The Bull Market With These 2 Momentum ETFs Benzinga
Nov-19-14 06:33PM  Four International IBD 50 Stocks Near Buy Points at Investor's Business Daily
Nov-17-14 06:27PM  Five Ethical Drugmakers Keep Leadership Positions at Investor's Business Daily
Nov-14-14 06:15AM  Is Jazz Pharmaceuticals (JAZZ) a Great Growth Stock? Zacks
Nov-13-14 03:30PM  Sucampo-Takeda Sue Dr. Reddy's for Amitiza Patent Violation Zacks
Nov-11-14 01:04PM  JAZZ PHARMACEUTICALS PLC Financials EDGAR Online Financials
Nov-06-14 04:05PM  Jazz Pharmaceuticals Announces Participation in Two Investor Conferences PR Newswire
12:05PM  3 Stocks Moving The Drugs Industry Upward at TheStreet
Nov-05-14 04:29PM  New balance of power on Capitol Hillbut no change in stock prices Yahoo Finance Blogs
01:20PM  Jazz Pharmaceuticals Q3 Earnings Rise Y/Y, Lifts Guidance Zacks
11:33AM  Jazz Pharma upgraded by R. F. Lafferty Briefing.com
10:38AM  Stocks Open To Staggered Gains; Time Warner, NXP, Jazz Climb at Investor's Business Daily
08:50AM  Jazz Pharmaceuticals Public (JAZZ) Earnings Report: Q3 2014 Conference Call Transcript at TheStreet
Nov-04-14 08:14PM  These 5 Drugmakers' Earnings Excelled This Quarter at Investor's Business Daily
07:02PM  Jazz Q3 Tops On Defitelio But Regeneron Cuts View Investor's Business Daily
05:11PM  Stocks End Mixed; Jazz Pharma Rises After Hours at Investor's Business Daily
04:30PM  Jazz Pharmaceuticals PLC Earnings Call scheduled for 4:30 pm ET today CCBN
04:13PM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and EDGAR Online
04:05PM  Jazz Pharmaceuticals Announces Third Quarter 2014 Financial Results And Updated Guidance PR Newswire
07:07AM  Q3 2014 Jazz Pharmaceuticals PLC Earnings Release - After Market Close CCBN
Nov-03-14 04:31PM  It was a lackluster trading session for U.S. equities Yahoo Finance Blogs
02:32PM  Video: 4 Top-Rated Stocks Reporting Earnings Tuesday at Investor's Business Daily
Oct-29-14 08:15AM  Analysts Top 4 Specialty Pharmaceutical Stocks to Buy Before Earnings at 24/7 Wall St.
Oct-21-14 04:05PM  Jazz Pharmaceuticals to Report 2014 Third Quarter Financial Results on November 4, 2014 PR Newswire
Oct-17-14 10:15AM  Insider Trading Alert - AYI, MDSO And JAZZ Traded By Insiders at TheStreet
Oct-15-14 05:04PM  Concert Pharmaceuticals Announces Positive CTP-354 Data Zacks
Oct-10-14 05:37PM  Inversion Vitriol Vs. Drug Consolidation Investor's Business Daily
Oct-09-14 12:15PM  Will Jazz Pharmaceuticals Dance Up The Chart? at Investor's Business Daily
Oct-07-14 06:08PM  Actavis, Jazz, Novo Lead Top World Stocks List at Investor's Business Daily
11:16AM  Zoetis Will Benefit from Industry Trends Gurufocus
Oct-04-14 08:02AM  Medical Stocks End Week On High Note, Biotechs Lead at Investor's Business Daily
Oct-03-14 02:39PM  Jazz Pharmaceuticals Uses New Cash To Buy For Growth at Investor's Business Daily
Oct-02-14 06:25PM  Top Fund Buys: Chipotle, Allergan, Jazz, Gilead at Investor's Business Daily
Sep-24-14 03:45PM  OPKO Health (OPK) Reports Positive Data on Rayaldee Trial Zacks
01:20PM  Stocks Hold Solid Gains; CyberArk Soars In Debut at Investor's Business Daily
Sep-23-14 04:00PM  Dynavax (DVAX) Completes Enrolment for Study on Heplisav Zacks
11:47AM  Video: Allergan-Ackman War Reignites On Salix Rumors at Investor's Business Daily
Sep-19-14 07:36PM  IBD 50 Stocks Setting Up, Including These 5 Medicals at Investor's Business Daily
Sep-18-14 06:53PM  Five Leading International Stocks Near Buy Points at Investor's Business Daily
10:00AM  Capitalize On Wall Street's Latest Tax Craze StreetAuthority Network
Sep-16-14 11:36AM  Video: Valeant, Allergan Settle Suit, Allow Shareholder Vote at Investor's Business Daily
11:15AM  Insider Trading Alert - TDC, MJN And JAZZ Traded By Insiders at TheStreet
Sep-15-14 02:37PM  IBD 50 Names Hold Gains, But Actionable Charts Scarce at Investor's Business Daily -5.35%
Sep-13-14 08:02AM  Gilead, Jazz, Salix Among Top 6 IBD 50 Drugmakers at Investor's Business Daily
Sep-12-14 07:11PM  IBD 50 Names Hold Gains, But Actionable Charts Scarce at Investor's Business Daily
Sep-11-14 10:38PM  Allergan investors owning 35 pct to demand special meeting Reuters
Sep-08-14 06:41AM  Jazz Pharmaceuticals (JAZZ) in Focus: Stock Rises 7.1% Zacks
Sep-05-14 04:15PM  Stocks Reverse Higher, But Some Retailers Sell Off at Investor's Business Daily +7.11%
Sep-03-14 06:28PM  Three Stocks Top-Performing Funds Like: Facebook Baidu Gilead at Investor's Business Daily
Sep-02-14 07:00AM  Get that shopping list ready to buy on the dip at CNBC
Aug-29-14 06:49PM  Baidu, AerCap And Jazz Among Basing Top World Stocks at Investor's Business Daily
Aug-27-14 08:02AM  Gilead, Jazz Among 4 Top Big Cap Medicals To Watch at Investor's Business Daily
Aug-21-14 08:07AM  Jazz Pharmaceuticals (JAZZ) Shares March Higher, Can It Continue? Zacks
Aug-20-14 05:29PM  Allergan Talks to Buy Salix in Defense Move Said to Be Dormant at Bloomberg
01:11PM  Major Indexes Turn Mixed; Jazz Pharmaceuticals Turns Up at Investor's Business Daily
09:38AM  [video] Faber Report: WSJ says Allergan approaches Salix at CNBC
Aug-19-14 05:03PM  Indexes Rally On Strong Housing Data, Retail Reports at Investor's Business Daily
03:13PM  Stocks Add To Gains; Salix Surges On Potential Bid at Investor's Business Daily
02:02PM  JP Morgan Says Jazz Pharmaceuticals Positioned For 'Organic Growth And Acquisition' Benzinga
12:54PM  Why Jazz Pharmaceuticals (JAZZ) Stock Is Gaining Today at TheStreet
09:27AM  Will This Coverage Initiation Help Jazz Pharmaceuticals (JAZZ) Stock Today? at TheStreet
Aug-18-14 01:46PM  Jazz, Celgene Lead Top 4 Drugmaker Profit Margins at Investor's Business Daily
Aug-15-14 11:48AM  Stocks Backslide Into Losses; Jazz Pharma, Kinder Morgan Rise at Investor's Business Daily
09:51AM  Jazz Pharmaceuticals (JAZZ) Is Today's Momo Momentum Stock at TheStreet
Aug-14-14 07:02AM  Jazz Pharmaceuticals (JAZZ) in Focus: Stock Surges 8.8% Zacks
Aug-13-14 04:36PM  [video] Airline Stocks Soar, Boosting U.S. Stock Market Rally at TheStreet +8.81%
04:10PM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financi EDGAR Online
03:55PM  Watch Out: Barbarians At The Gate For Jazz Pharmaceuticals (JAZZ) at TheStreet
01:29PM  Nasdaq Leads Indexes As Solar, Biotechs Outperform at Investor's Business Daily
11:12AM  Jazz Pharmaceuticals PLC Stock Upgraded (JAZZ) at TheStreet
Aug-12-14 06:41AM  Why Jazz Pharmaceuticals (JAZZ) Could Be an Impressive Growth Stock Zacks
Aug-08-14 04:34PM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
10:29AM  Scott Drake, CEO, and Guy A. Childs, CFO of The Spectranetics Corporation (SPNC), Interview with The Wall Street Transcript Wall Street Transcript
06:30AM  Jazz Pharmaceuticals Announces Pricing of $500 Million of Exchangeable Senior Notes PR Newswire
Aug-07-14 04:20PM  Afternoon Selling Holds Stocks In Check at Investor's Business Daily -5.18%
10:23AM  Jazz Financing I Ltd. -- Moody's upgrades Jazz credit facilities to Ba2; affirms Ba3 CFR at Moody's
07:32AM  Jazz Pharmaceuticals (JAZZ) Jumps: Stock Moves 5.2% Higher Zacks
07:00AM  3 Big-Volume Biotech Stocks to Trade for Breakouts at TheStreet
Aug-06-14 05:13PM  Roses in the Market Yahoo Finance Blogs +5.18%
05:07PM  Stocks Muted; Keurig Green Mountain Down After Hours at Investor's Business Daily
04:17PM  Indexes Close Flat After Seesaw Session at Investor's Business Daily
04:05PM  Jazz Pharmaceuticals Announces Proposed Offering of $500 Million of Exchangeable Senior Notes PR Newswire
01:36PM  Jazz Pharma Jumps After Q2 Earnings Rebound at Investor's Business Daily
10:13AM  Barbarian At The Gate: Jazz Pharmaceuticals (JAZZ) at TheStreet
09:33AM  Jazz Pharmaceuticals Spikes In #PreMarket On Q2 Beat; Boosts Revenue Outlook Benzinga
08:30AM  Earnings Up at Jazz Pharmaceuticals, Revenue Guidance Raised Zacks
Aug-05-14 04:49PM  Ukraine Jitters Send Stocks Lower In Afternoon Trade at Investor's Business Daily
04:46PM  Ukraine Tension Prominent As Dow Suffers Triple Point Digit Loss; S&P 500 & Nasdaq Also Lower Benzinga
04:30PM  Jazz Pharmaceuticals PLC Earnings Call scheduled for 4:30 pm ET today CCBN
04:28PM  Stocks Fall In Fast Trade; First Solar Down On Earnings at Investor's Business Daily
04:25PM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Financial Statements EDGAR Online
04:05PM  Jazz Pharmaceuticals Announces Second Quarter 2014 Financial Results And Updated Guidance PR Newswire
04:01PM  Jazz Pharmaceuticals Completes Acquisition Of Rights To Defibrotide In The Americas From Sigma-Tau Pharmaceuticals, Inc. PR Newswire
10:29AM  Actavis Guidance Disappoints; Akorn Beats And Raises at Investor's Business Daily
07:07AM  Q2 2014 Jazz Pharmaceuticals Earnings Release - After Market Close CCBN
Aug-04-14 04:10PM  Jazz Pharmaceuticals Announces Participation at Canaccord Genuity Conference on August 13 PR Newswire
Aug-02-14 08:02AM  Salix, Actavis Lead IBD 50 Drug Earnings This Week at Investor's Business Daily
Aug-01-14 08:41AM  The Zacks Analyst Blog Highlights: Medtronic, Covidien, Mylan, Actavis and Jazz Pharmaceuticals Zacks
Jul-30-14 05:33PM  A Cup-With-Handle Breakout Can Lead To Massive Gains Investor's Business Daily
Jul-23-14 09:05PM  Are P/E Ratios Leading You Away From Your Biggest Winners? at Seeking Alpha
Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. Its products comprise Xyrem for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment and prevention of VOD, a potentially life-threatening complication of HSCT; Prialt for the management of severe chronic pain; and FazaClo LD and FazaClo HD tablets for the treatment-resistant schizophrenia, as well as Versacloz for treatment-resistant schizophrenia. The company also develops JZP-110, an investigational compound, which is in clinical development for the treatment of EDS in patients with narcolepsy; and JZP-386, a deuterium-modified analog of sodium oxybate products that is under pre-clinical research and development and is intended for the treatment of narcolepsy patients. In addition, it offers products in the areas of hematology and oncology drugs, such as Asparec, which is in Phase I clinical trial for the treatment of patients with ALL with E.coli asparaginase hypersensitivity; Defibrotide for the treatment of severe VOD; and Leukotac, an anti-CD25 monoclonal antibody that is in Phase III clinical trials and is intended for the treatment of steroid-refractory acute GvHD. The company is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Tobias Jeffrey KEVP, Research & Dev and CMONov 14Sale173.321,000173,32039,538Nov 18 05:40 PM
Hooper Suzanne SawochkaEVP and General CounselNov 11Option Exercise46.8366731,23650,101Nov 13 06:55 PM
Hooper Suzanne SawochkaEVP and General CounselNov 11Sale173.631,852321,56348,249Nov 13 06:55 PM
COZADD BRUCE CChairman and CEONov 11Sale173.635,000868,150564,023Nov 13 06:45 PM
ENRIGHT PATRICK GDirectorNov 10Sale171.0910,0001,710,8587,268Nov 12 04:04 PM
McGill IainHead of EUSA Int'l & SVPNov 07Option Exercise50.095,666283,78930,490Nov 10 06:25 PM
McGill IainHead of EUSA Int'l & SVPNov 07Sale172.037,0661,215,53023,424Nov 10 06:25 PM
WILSON KAREN JSVP, Finance & PAONov 06Option Exercise50.347,000352,41028,713Nov 10 05:48 PM
WILSON KAREN JSVP, Finance & PAONov 06Sale170.117,5961,292,15721,117Nov 10 05:48 PM
COZADD BRUCE CChairman and CEOOct 14Sale142.775,000713,850569,023Oct 16 07:06 PM
Tobias Jeffrey KEVP, Research & Dev and CMOOct 10Sale154.041,000154,04040,538Oct 14 06:35 PM
ENRIGHT PATRICK GDirectorOct 06Sale160.5610,0001,605,6337,465Oct 08 06:01 AM
Mulligan SeamusDirectorSep 25Sale161.8414,7062,380,0641,307,205Sep 26 06:45 PM
Mulligan SeamusDirectorSep 24Sale163.7035,2945,777,6921,321,911Sep 26 06:45 PM
Tobias Jeffrey KEVP, Research & Dev and CMOSep 12Sale171.221,000171,22041,538Sep 15 07:10 PM
WILSON KAREN JSVP, Finance & PAOSep 11Option Exercise27.463,00082,38024,713Sep 15 06:53 PM
Mulligan SeamusDirectorSep 11Sale175.0050,0008,750,0001,357,205Sep 15 06:56 PM
WILSON KAREN JSVP, Finance & PAOSep 11Sale175.003,000525,00021,713Sep 15 06:53 PM
COZADD BRUCE CChairman and CEOSep 09Sale170.325,000851,600574,023Sep 10 09:07 PM
Hooper Suzanne SawochkaEVP and General CounselSep 08Option Exercise46.8366731,23652,471Sep 10 09:05 PM
WILSON KAREN JSVP, Finance & PAOSep 08Option Exercise27.462,50068,65024,213Sep 10 09:06 PM
WILSON KAREN JSVP, Finance & PAOSep 08Sale170.002,500425,00021,713Sep 10 09:06 PM
Hooper Suzanne SawochkaEVP and General CounselSep 08Sale168.001,852311,13650,619Sep 10 09:05 PM
ENRIGHT PATRICK GDirectorSep 02Sale162.9410,0001,629,3877,661Sep 04 04:47 PM
Hooper Suzanne SawochkaEVP and General CounselAug 15Option Exercise46.8366731,23652,471Aug 19 07:04 PM
Hooper Suzanne SawochkaEVP and General CounselAug 15Sale150.00667100,05051,804Aug 19 07:04 PM
Hooper Suzanne SawochkaEVP and General CounselAug 12Sale133.151,185157,78351,804Aug 13 06:37 PM
COZADD BRUCE CChairman and CEOAug 12Sale133.155,000665,750579,023Aug 13 06:33 PM
Winningham Rick EDirectorAug 12Sale133.151,087144,73414,150Aug 14 06:08 PM
Sohn Catherine A.DirectorAug 12Sale133.151,731230,4835,529Aug 14 06:07 PM
ENRIGHT PATRICK GDirectorAug 12Sale133.151,087144,7343,993Aug 14 06:03 PM
BERNS PAUL LDirectorAug 12Sale133.151,087144,7343,993Aug 14 06:01 PM
Tobias Jeffrey KEVP, Research & Dev and CMOAug 11Option Exercise52.744,933260,18847,471Aug 13 06:51 PM
Tobias Jeffrey KEVP, Research & Dev and CMOAug 11Sale135.424,933668,02742,538Aug 13 06:51 PM
Hooper Suzanne SawochkaEVP and General CounselJul 08Option Exercise46.831,85386,77659,407Jul 10 08:09 PM
Keegan FintanEVP, Technical OperationsJul 08Option Exercise46.8346921,96333,741Jul 10 08:14 PM
Keegan FintanEVP, Technical OperationsJul 08Sale155.001,991308,60531,750Jul 10 08:14 PM
Hooper Suzanne SawochkaEVP and General CounselJul 08Sale155.001,853287,21557,554Jul 10 08:09 PM
COZADD BRUCE CChairman and CEOJul 08Sale155.005,000775,000597,067Jul 10 08:04 PM
WILSON KAREN JSVP, Finance & PAOJul 07Option Exercise27.462,50068,65026,169Jul 09 08:12 PM
WILSON KAREN JSVP, Finance & PAOJul 07Sale165.002,500412,50023,669Jul 09 08:12 PM
Mulligan SeamusDirectorJun 25Sale148.64476,9861,405,555Jun 26 08:21 PM
Mulligan SeamusDirectorJun 24Sale149.7049,9537,477,7491,405,602Jun 26 08:21 PM
Cox Russell J.EVP & Chief Operating OfficerJun 20Sale155.002,000310,00057,032Jun 24 07:06 PM
Keegan FintanEVP, Technical OperationsJun 17Sale150.003,750562,50033,272Jun 19 04:01 PM
COZADD BRUCE CChairman and CEOJun 10Sale142.345,000711,700602,067Jun 11 04:36 PM
Tobias Jeffrey KEVP, Research & Dev and CMOJun 09Option Exercise48.633,000145,89050,103Jun 11 06:30 PM
Tobias Jeffrey KEVP, Research & Dev and CMOJun 09Sale146.243,000438,72047,103Jun 11 06:30 PM
RIEDEL NORBERT GDirectorMay 28Sale142.4964491,7643,356May 29 07:27 PM
Hooper Suzanne SawochkaEVP and General CounselMay 27Option Exercise46.8366731,23657,802May 29 07:24 PM
Hooper Suzanne SawochkaEVP and General CounselMay 27Sale140.0066793,38057,135May 29 07:24 PM
COZADD BRUCE CChairman and CEOMay 13Sale128.925,000644,600606,810May 14 06:09 PM
Keegan FintanEVP, Technical OperationsMay 08Sale136.03750102,02337,772May 12 08:13 PM
Hooper Suzanne SawochkaEVP and General CounselApr 17Option Exercise46.8366731,23657,802Apr 21 07:59 PM
Hooper Suzanne SawochkaEVP and General CounselApr 17Sale140.0066793,38057,135Apr 21 07:59 PM
Winningham Rick EDirectorApr 17Sale140.0027,5003,850,00013,587Apr 21 07:55 PM
Tobias Jeffrey KEVP, Research & Dev and CMOApr 14Option Exercise53.883,000161,64651,103Apr 16 07:41 PM
Tobias Jeffrey KEVP, Research & Dev and CMOApr 14Sale128.543,000385,62048,103Apr 16 07:41 PM
Keegan FintanEVP, Technical OperationsApr 08Sale130.0075097,50038,522Apr 10 08:37 PM
COZADD BRUCE CChairman and CEOApr 08Sale123.185,000615,900611,810Apr 10 08:34 PM
Tobias Jeffrey KEVP, Research & Dev and CMOMar 10Option Exercise53.883,000161,63451,103Mar 12 06:06 PM
Tobias Jeffrey KEVP, Research & Dev and CMOMar 10Sale152.993,000458,97048,103Mar 12 06:06 PM
WILSON KAREN JSVP, Finance & PAOMar 07Option Exercise59.133,000177,39027,300Mar 11 08:26 PM
WILSON KAREN JSVP, Finance & PAOMar 07Sale155.043,888602,79623,412Mar 11 08:26 PM
Keegan FintanEVP, Technical OperationsMar 06Sale157.891,634257,99239,272Mar 06 07:01 PM
Mulligan SeamusDirectorMar 04Sale156.25550,00085,937,5001,455,555Mar 05 05:19 PM
Keegan FintanEVP, Technical OperationsMar 04Sale161.003,006483,96640,906Mar 06 07:01 PM
WILSON KAREN JSVP, Finance & PAOFeb 27Option Exercise46.8311,250526,83832,582Mar 03 08:14 PM
WILSON KAREN JSVP, Finance & PAOFeb 27Sale166.7711,2501,876,15021,332Mar 03 08:14 PM
Tobias Jeffrey KEVP, Research & Dev and CMOFeb 27Sale165.463,000496,38041,777Mar 03 08:05 PM
COZADD BRUCE CChairman and CEOFeb 27Sale158.3625,0003,959,000600,754Mar 03 07:21 PM
Cox Russell J.EVP & Chief Commercial OfficerFeb 27Sale164.594,000658,36050,024Mar 03 07:10 PM
FALBERG KATHRYN EEVP and CFOFeb 26Option Exercise7.3510,20474,999134,925Feb 27 08:08 PM
FALBERG KATHRYN EEVP and CFOFeb 12Sale157.002,000314,000124,721Feb 14 07:09 PM
Tobias Jeffrey KEVP, Research & Dev and CMOFeb 10Option Exercise46.832,560119,88547,337Feb 12 07:18 PM
Tobias Jeffrey KEVP, Research & Dev and CMOFeb 10Sale152.832,560391,24544,777Feb 12 07:18 PM
FALBERG KATHRYN EEVP and CFOJan 08Sale131.822,000263,640126,721Jan 10 08:26 PM
FALBERG KATHRYN EEVP and CFODec 11Sale120.503,000361,500128,721Dec 13 07:49 PM
Tobias Jeffrey KEVP, Research & Dev and CMODec 09Option Exercise46.831,32562,05046,102Dec 11 07:01 PM
Tobias Jeffrey KEVP, Research & Dev and CMODec 09Sale117.801,325156,08544,777Dec 11 07:01 PM